EE03420B1 - Farmatseutiline kompositsioon maania ja bipolaarse häire raviks - Google Patents

Farmatseutiline kompositsioon maania ja bipolaarse häire raviks

Info

Publication number
EE03420B1
EE03420B1 EE9700302A EE9700302A EE03420B1 EE 03420 B1 EE03420 B1 EE 03420B1 EE 9700302 A EE9700302 A EE 9700302A EE 9700302 A EE9700302 A EE 9700302A EE 03420 B1 EE03420 B1 EE 03420B1
Authority
EE
Estonia
Prior art keywords
bipolar disorder
pharmaceutical composition
treating mania
mania
treatment
Prior art date
Application number
EE9700302A
Other languages
English (en)
Estonian (et)
Other versions
EE9700302A (et
Inventor
Chandra Pande Atul
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE9700302A publication Critical patent/EE9700302A/xx
Publication of EE03420B1 publication Critical patent/EE03420B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EE9700302A 1995-05-15 1996-04-26 Farmatseutiline kompositsioon maania ja bipolaarse häire raviks EE03420B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/440,570 US5510381A (en) 1995-05-15 1995-05-15 Method of treatment of mania and bipolar disorder
PCT/US1996/005898 WO1996036328A1 (en) 1995-05-15 1996-04-26 A method of treatment of mania and bipolar disorder

Publications (2)

Publication Number Publication Date
EE9700302A EE9700302A (et) 1998-06-15
EE03420B1 true EE03420B1 (et) 2001-06-15

Family

ID=23749281

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700302A EE03420B1 (et) 1995-05-15 1996-04-26 Farmatseutiline kompositsioon maania ja bipolaarse häire raviks

Country Status (19)

Country Link
US (1) US5510381A (no)
EP (1) EP0825857B1 (no)
JP (1) JPH11505244A (no)
AT (1) ATE218857T1 (no)
AU (1) AU702435B2 (no)
CA (1) CA2215923C (no)
CZ (1) CZ288072B6 (no)
DE (1) DE69621799T2 (no)
DK (1) DK0825857T3 (no)
EE (1) EE03420B1 (no)
ES (1) ES2177783T3 (no)
GE (1) GEP20002014B (no)
HU (1) HUP9802087A3 (no)
NO (1) NO315967B1 (no)
NZ (1) NZ307366A (no)
PT (1) PT825857E (no)
SK (1) SK281982B6 (no)
WO (1) WO1996036328A1 (no)
ZA (1) ZA963826B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
WO1999018063A2 (en) 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
CU23048A3 (es) 1997-10-27 2005-06-24 Warner Lambert Co Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
EP1077691B1 (en) * 1998-05-15 2008-09-10 Warner-Lambert Company LLC Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
DK1077692T3 (da) 1998-05-15 2004-12-06 Warner Lambert Co Aminosyrestabiliserede gabapentin- og pregabalinpræparater og fremgangsmåder til fremstilling deraf
WO1999061424A1 (en) 1998-05-26 1999-12-02 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
KR20010071778A (ko) * 1998-07-09 2001-07-31 로즈 암스트롱, 크리스틴 에이. 트러트웨인 불면증의 치료를 위한 gaba 유사체의 용도
EP1121114B1 (en) * 1998-10-16 2007-01-10 Warner-Lambert Company Llc Use of gaba analogs for the manufacture of a medicament for the treatment of mania and bipolar disorders
WO2000073300A1 (en) * 1999-06-02 2000-12-07 Warner-Lambert Company Amino heterocycles useful as pharmaceutical agents
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
HUP0301919A3 (en) * 2000-06-16 2006-01-30 Teva Pharma Stable gabapentin having ph within a controlled range
SK17922002A3 (sk) * 2000-06-26 2003-11-04 Warner-Lambert Company Obdoby gabapentínu na liečenie porúch spánku
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP2575798B1 (en) 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
WO2015144825A1 (en) 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
US11670410B1 (en) * 2022-04-13 2023-06-06 Green Sky Creations LLC Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression

Also Published As

Publication number Publication date
EP0825857A1 (en) 1998-03-04
EP0825857B1 (en) 2002-06-12
ES2177783T3 (es) 2002-12-16
PT825857E (pt) 2002-11-29
NZ307366A (en) 1999-10-28
NO315967B1 (no) 2003-11-24
CZ355897A3 (cs) 1998-02-18
CA2215923A1 (en) 1996-11-21
ATE218857T1 (de) 2002-06-15
DE69621799D1 (de) 2002-07-18
WO1996036328A1 (en) 1996-11-21
ZA963826B (en) 1996-11-21
DE69621799T2 (de) 2003-01-02
HUP9802087A2 (hu) 1998-12-28
SK152897A3 (en) 1999-05-07
EE9700302A (et) 1998-06-15
GEP20002014B (en) 2000-04-10
MX9707269A (es) 1997-11-29
DK0825857T3 (da) 2002-09-30
CZ288072B6 (cs) 2001-04-11
AU5668996A (en) 1996-11-29
CA2215923C (en) 2001-10-09
AU702435B2 (en) 1999-02-18
JPH11505244A (ja) 1999-05-18
NO975234D0 (no) 1997-11-14
NO975234L (no) 1997-11-14
SK281982B6 (sk) 2001-09-11
HUP9802087A3 (en) 1999-08-30
US5510381A (en) 1996-04-23

Similar Documents

Publication Publication Date Title
EE03420B1 (et) Farmatseutiline kompositsioon maania ja bipolaarse häire raviks
CY1106020T1 (el) Χρηση αναλογων caba για την βιομηχανικη κατασκευη ενος φαρμακου για την θepαπεια μανιας και διπολικων διαταραχων
BR9708632A (pt) Composto calcilìticos
ATE212837T1 (de) Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
DE69201660D1 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
ATE275966T1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
ES2195000T3 (es) Composicion farmaceutica.
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
ES2090703T3 (es) Medicamento agudo que contiene flurbiprofeno y su empleo.
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
BR9811643A (pt) Suplementação quìmica de osso
ATE218881T1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
BR9713514A (pt) Novo uso de creatina
MX9201825A (es) Composicion farmaceutica que contiene calcitonina.
NO984197D0 (no) Fremgangsmåte for behandling av autisme
BR9701455A (pt) Uso de antagonistas de bradicinina para a preparaçao de medicamentos para o tratamento de doenças fibrogenéticas crônicas do fígado e doenças agudas do fígado
NZ328198A (en) a pharmaceutical composition containing hydroxyzine and a serotonin uptake inhibitor
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
ATE245421T1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
ES2085657T3 (es) Un medicamento de accion retardada que contiene flurbiprofeno y su utilizacion.
YU40098A (sh) Upotreba olanzapina za dobijanje leka

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

MM4A Lapsed by not paying the annual fees

Effective date: 20080426